<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>immune-related risk score &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/immune-related-risk-score/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 11:55:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>immune-related risk score &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>CD2AP Alters Tumor Microenvironment, Boosts Immunotherapy</title>
		<link>https://bioengineer.org/cd2ap-alters-tumor-microenvironment-boosts-immunotherapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 21 May 2025 20:47:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CD2AP]]></category>
		<category><![CDATA[gastric cancer immunotherapy]]></category>
		<category><![CDATA[immune-related risk score]]></category>
		<category><![CDATA[stromal reduced microenvironment]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cd2ap-alters-tumor-microenvironment-boosts-immunotherapy/</guid>

					<description><![CDATA[In the relentless pursuit of combating gastric cancer, a disease notorious for its high mortality and global prevalence, new molecular insights are emerging that may revolutionize existing therapeutic strategies. Recent groundbreaking research led by Li, Chen, Zhao, and colleagues at BMC Cancer has spotlighted the CD2 Associated Protein (CD2AP) as a pivotal player in modulating [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">246206</post-id>	</item>
	</channel>
</rss>
